Biology of Blood and Marrow Transplantation
Volume 16, Issue 9 , Pages 1245-1256 , September 2010

Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in Humans

  • Michael C. Jensen

      Affiliations

    • Department of Cancer Immunotherapeutics and Tumor Immunology, Beckman Research Institute, City of Hope National Medical Center, Duarte, California
    • Department of Hematology and Hematopoietic Cell Transplant, Beckman Research Institute, City of Hope National Medical Center, Duarte, California
    • Corresponding Author InformationCorrespondence and reprint requests: Michael C. Jensen, MD, Department of Cancer Immunotherapeutics and Tumor Immunology, Beckman Research Institute, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA 91010-3000.
    • ,
  • Leslie Popplewell

      Affiliations

    • Department of Hematology and Hematopoietic Cell Transplant, Beckman Research Institute, City of Hope National Medical Center, Duarte, California
    • ,
  • Laurence J. Cooper

      Affiliations

    • Department of Hematology and Hematopoietic Cell Transplant, Beckman Research Institute, City of Hope National Medical Center, Duarte, California
    • ,
  • David DiGiusto

      Affiliations

    • Department of Hematology and Hematopoietic Cell Transplant, Beckman Research Institute, City of Hope National Medical Center, Duarte, California
    • ,
  • Michael Kalos

      Affiliations

    • Department of Cancer Immunotherapeutics and Tumor Immunology, Beckman Research Institute, City of Hope National Medical Center, Duarte, California
    • ,
  • Julie R. Ostberg

      Affiliations

    • Department of Cancer Immunotherapeutics and Tumor Immunology, Beckman Research Institute, City of Hope National Medical Center, Duarte, California
    • ,
  • Stephen J. Forman

      Affiliations

    • Department of Cancer Immunotherapeutics and Tumor Immunology, Beckman Research Institute, City of Hope National Medical Center, Duarte, California
    • Department of Hematology and Hematopoietic Cell Transplant, Beckman Research Institute, City of Hope National Medical Center, Duarte, California

Received 26 January 2010 ,Accepted 11 March 2010.

References 

  1. Kofler DM, Mayr C, Wendtner CM. Current status of immunotherapy in B cell malignancies. Curr Drug Targets. 2006;7:1371–1374
  2. Molina A. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma. Annu Rev Med. 2008;59:237–250
  3. Cesco-Gaspere M, Morris E, Stauss HJ. Immunomodulation in the treatment of haematological malignancies. Clin Exp Med. 2009;9:81–92
  4. Timmerman JM. Immunotherapy for lymphomas. Int J Hematol. 2003;77:444–455
  5. Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol. 2009;21:215–223
  6. Riddell SR. Engineering antitumor immunity by T-cell adoptive immunotherapy. Hematol Am Soc Hematol Educ Progr. 2007;250–256
  7. Jensen M, Tan G, Forman S, et al. CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy. Biol Blood Marrow Transplant. 1998;4:75–83
  8. Cooper LJ, Topp MS, Serrano LM, et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood. 2003;101:1637–1644
  9. Jensen MC, Clarke P, Tan G, et al. Human T lymphocyte genetic modification with naked DNA. J Mol Ther. 2000;1:49–55
  10. Gonzalez S, Naranjo A, Serrano LM, et al. Genetic engineering of cytolytic T lymphocytes for adoptive T-cell therapy of neuroblastoma. J Gene Med. 2004;6:704–711
  11. Cooper LJ, Ausubel L, Gutierrez M, et al. Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma. Cytotherapy. 2006;8:105–117
  12. Park JR, Digiusto DL, Slovak M, et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther. 2007;15:825–833
  13. Akatsuka Y, Martin EG, Madonik A, et al. Rapid screening of T-cell receptor (TCR) variable gene usage by multiplex PCR: application for assessment of clonal composition. Tissue Antigens. 1999;53:122–134
  14. Betts MR, Brenchley JM, Price DA, et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods. 2003;281:65–78
  15. Alexander DD, Mink PJ, Adami HO, et al. The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer. 2007;120(Suppl 12):1–39
  16. Rogers BB. Overview of non-Hodgkin's lymphoma. Semin Oncol Nurs. 2006;22:67–72
  17. Arora NK, Hamilton AS, Potosky AL, et al. Population-based survivorship research using cancer registries: a study of non-Hodgkin's lymphoma survivors. J Cancer Surviv. 2007;1:49–63
  18. Gisselbrecht C, Bethge W, Duarte RF, et al. Current status and future perspectives for yttrium-90 ((90)Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant. 2007;40:1007–1017
  19. Paolo C, Lucia F, Anna D. Hematopoietic stem cell transplantation in peripheral T-cell lymphomas. Leuk Lymphoma. 2007;48:1496–1501
  20. Santos ES, Kharfan-Dabaja MA, Ayala E, et al. Current results and future applications of radioimmunotherapy management of non-Hodgkin's lymphoma. Leuk Lymphoma. 2006;47:2453–247
  21. Zinzani PL. Autologous hematopoietic stem cell transplantation in non-Hodgkin's lymphomas. Acta Haematol. 2005;114:255–259
  22. Bertoni F, Zucca E, Cavalli F. Mantle cell lymphoma. Curr Opin Hematol. 2004;11:411–418
  23. Brody J, Advani R. Treatment of mantle cell lymphoma: current approach and future directions. Crit Rev Oncol Hematol. 2006;58:257–265
  24. Goy A, Feldman T. Expanding therapeutic options in mantle cell lymphoma. Clin Lymphoma Myeloma. 2007;7(Suppl 5):S184–S191
  25. Smith MR. Mantle cell lymphoma: advances in biology and therapy. Curr Opin Hematol. 2008;15:415–421
  26. Brentjens RJ, Riviere I, Hollyman D, et al. Unexpected toxicity of cyclophosphamide followed by adoptively transferred CD19-targeted T cells in a patient with bulky CLL. Mol Ther. 2009;17:S157;[Abstract]
  27. Berger C, Flowers ME, Warren EH, et al. Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK–modified donor T cells after allogeneic hematopoietic cell transplantation. Blood. 2006;107:2294–2302
  28. Berger C, Huang ML, Gough M, et al. Nonmyeloablative immunosuppressive regimen prolongs in vivo persistence of gene-modified autologous T cells in a nonhuman primate model. J Virol. 2001;75:799–808
  29. Singh H, Manuri PR, Olivares S, et al. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res. 2008;68:2961–2971
  30. Wherry EJ, Teichgraber V, Becker TC, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol. 2003;4:225–234
  31. Gattinoni L, Powell DJ, Rosenberg SA, et al. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol. 2006;6:383–393
  32. Fearon DT, Manders P, Wagner SD. Arrested differentiation, the self-renewing memory lymphocyte, and vaccination. Science. 2001;293:248–250
  33. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14:1264–1270
  34. Berger C, Jensen MC, Lansdorp PM, et al. Adoptive transfer of effector CD8 T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest. 2008;118:294–305

 Laurence J. Cooper is currently at the Division of Pediatrics, M.D. Anderson Cancer Center, Houston, Texas. Michael Kalos is currently at the Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania.

 Financial disclosure: See Acknowledgments, page 1256.

PII: S1083-8791(10)00119-9

doi: 10.1016/j.bbmt.2010.03.014

Biology of Blood and Marrow Transplantation
Volume 16, Issue 9 , Pages 1245-1256 , September 2010

Article Tools

* Image Usage & Resolution